ArticleFrontiers in oncology2024
Potential biomarkers for predicting the risk of thyroid cancer in immunosenescence: a population-based and externally validated multi omics study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gastrointestinal dysfunction after brain injury: Mechanisms and the role of the brain-gut axis.World journal of gastroenterology · 2026Review
- TWAS atlas 2.0: an updated data resource for transcriptome-wide association studies.Nucleic acids research · 2026Article
- Cross-tissue transcriptome-wide analysis reveals novel insights into thyroid cancer etiology.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Genome-wide association studies (GWAS) have pinpointed several risk loci linked to thyroid cancer; however, the discovery of new plasma proteins implicated in immunosenescence continues to pose significant challenges. This study aims to uncover novel plasma proteins tied to aging, potentially contributing to thyroid cancer, utilizing diverse investigative methodologies. Methods: In this research, we utilized an integrative omics approach to identify novel plasma proteins associated with immunosenescence in relation to the risk of thyroid cancer. Additionally, we performed meta-analyses to pinpoint loci and genes affected by pleiotropic effects. Finally, complementary results were obtained from an independent cohort analyzed at Chongqing Medical University Yongchuan Hospital and Bulk-RNA seq from GEO database. Results: Causal analysis suggests that DNA methylation age acceleration as measured by the Hannum method increases the risk of thyroid cancer (OR: 1.126, 95% CI: 1.002-1.265, P=0.046). Subsequently, we conducted a meta-analysis on the relationship between Hannum DNA methylation age and thyroid cancer risk, which identified 138 potential risk loci through FUMA. Additionally, proteomics and transcriptomics collectively identified 6 potential targets related to immunosenescence and thyroid cancer. Subsequently, Bulk-seq results indicated differential expression of Conclusions: This study identified novel plasma proteins associated with immunosenescence that may be linked to thyroid cancer development. These findings enhance our understanding of the immunosenescence-thyroid cancer link and support future diagnostic and therapeutic developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.